Toronto-based PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF) has structured a special purpose vehicle to advance APA-01, a patented pre-IND MDXX-class small molecule, into US clinical development — bypassing a conventional out-license in favor of a co-founded entity that preserves equity upside while offloading capital-raising responsibility to a private partner.
Under the definitive agreement executed May 13, PharmAla and private firm Aluvaris Inc. will each hold 50% of the founding shares of Restora Neurosciences, the newly formed SPV. Mississauga-based contract research organization Diteba Inc. has been appointed as the SPV's anchor scientific and bioanalytical services provider. The transaction follows a binding letter of intent announced April 27 and closed ahead of the parties' agreed June 8 outside date.
PharmAla will receive a one-time license fee of USD 500,000, payable by Restora upon the SPV raising a minimum of USD 2.5 million from third-party investors. A perpetual royalty of 3% of net sales applies on a country-by-country, product-by-product basis. PharmAla's equity stake is protected by an anti-dilution floor of 25% through the first priced financing round following the funding threshold. No milestone payments tied to regulatory or commercial events were disclosed.
Deal context
APA-01 is chemically identified as (R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine and is covered by US Patent No. 12,042,478 and a related international patent estate. The compound is described by PharmAla as a novel MDXX-class small molecule with activity at serotonin, dopamine, and norepinephrine transporters, and interactions with 5-HT₂A/B/C receptors and TAAR1 — a target profile consistent with published literature on entactogen pharmacology, though independent peer-reviewed data on APA-01 specifically have not been disclosed. The compound is not currently scheduled as a controlled substance in either the US or Canada, which PharmAla characterizes as relevant to its regulatory pathway.
Target indications include post-stroke neurorehabilitation and traumatic brain injury. PharmAla has also noted alignment with a Presidential Executive Order signed April 18, 2026, directing the US FDA to issue Commissioner's National Priority Vouchers to qualifying programs receiving Breakthrough Therapy designation, with TBI in military veterans named as a priority. No regulatory designations have been granted to APA-01 to date. The SPV's primary near-term obligation is filing a first IND with the US FDA within 36 months of the funding threshold being met, with a six-month remediation extension available. Failure to meet that milestone is a reversion trigger returning all rights to PharmAla.